4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-019598
CHIEF FINANCIAL OFFICER sold 3,000 shares at $25.07 ($75,195)
- CHIEF FINANCIAL OFFICER acquired 3,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hohl Benjamin · CHIEF FINANCIAL OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-07-12 | Exercise or conversion : show line 1 in the form 10b5-1 | +3,000 | $2.48 | $7,440 | 3,000 | D |
| 2024-07-12 | Sale : show line 2 in the form 10b5-1 | −3,000 | $25.07 | $75,195 | 0 | D |
| Open-market sales · 3,000 sh · avg $25.07 · $75,195 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-07-12 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −3,000 | 209,620 | D |
Loading xslF345X05/form4-07162024_090739.xml…